amatuximab
mAbexperimental
Amatuximab is a chimeric monoclonal antibody designed for the treatment of cancer. It was developed by Morphotek, Inc. — Wikipedia
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2006 (NCT00325494)
Timeline
Indications
Mechanism of action
- MesothelinINHIBITOR
MSLN inhibitor
MORAb-009 can internalize after binding mesothelin on the cell surface. MORAb-009 can exert antibody-dependent cellular cytotoxicity. MORAb-009 blocks CA125/MUC16-mesothelin interaction.
- MesothelinImmunity, passive
MSLN immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAmatuximab ↗
- ChEMBLCHEMBL1742984 ↗
Also known as
- amatuximab
- amatuximab
- amatuximab
- amatuximab
- morab-009
- morab-009
- morab-009
- morab-009 monoclonal antibody
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02357147 | Phase 2 | Nov 4, 2015 | Morphotek |
| NCT01521325 | Phase 1 | Sep 1, 2011 | Morphotek, National Institutes of Health (NIH) |
| NCT01413451 | Early Phase 1 (Phase 1) | Jul 12, 2011 | National Cancer Institute (NCI) |
| NCT01018784 | Phase 1 | Nov 1, 2009 | Eisai, Morphotek |
| NCT00738582 | Phase 2 | Dec 1, 2008 | Morphotek |
| NCT00570713 | Phase 2 | Dec 1, 2007 | Morphotek |
| NCT00325494 | Phase 1 | May 1, 2006 | Morphotek |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Morphotek | For profit | 6 | 5 | 2 | 2006 |
| Eisai | For profit | 1 | 1 | 1 | 2009 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2011 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2011 |
4 organizations
Page 1 / 1